1. Home
  2. Browse Decisions
  3. F.Supp.
  4. 874 F.Supp.
  5. 874 F.Supp. 630 (1995)
 

NOVO NORDISK v. GENENTECH, INC.

No. 94 Civ. 8634 (CBM).

874 F.Supp. 630 (1995)

NOVO NORDISK OF NORTH AMERICA, INC., Novo Nordisk Pharmaceuticals Inc., and Novo Nordisk A/S, Plaintiffs, v. GENENTECH, INC., Defendant.

United States District Court, S.D. New York.

February 2, 1995.

Attorney(s) appearing for the Case

Mark H. Sparrow, Rosenman & Colin, New York City, for plaintiffs.

James R. Ringer, Rogers & Wells, New York City, for defendant.

OPINION

MOTLEY, District Judge.

GENENTECH'S MOTION TO TRANSFER OR STAY

Both Novo Nordisk and Genentech are involved in the business of genetically-engineered pharmaceutical products. Novo Nordisk is waiting to get FDA approval to be able to sell Norditropin, genetically-engineered human growth hormone, inside of the United States. Genentech owns some U.S. patents concerning the production of human growth hormone.

In March 1993, Genentech...

Let's get started

Leagle.com

Welcome to the leading source of independent legal reporting
Sign on now to see your case.
Or view more than 10 million decisions and orders.

  • Updated daily.
  • Uncompromising quality.
  • Complete, Accurate, Current.

Listed below are the cases that are cited in this Featured Case. Click the citation to see the full text of the cited case. Citations are also linked in the body of the Featured Case.

Cited Cases

  • No Cases Found

Listed below are those cases in which this Featured Case is cited. Click on the case name to see the full text of the citing case.

Citing Cases